Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | GFER | P55789 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17402829 | 0.90 | GAA (0.81) | GAAGFERMEN1KMT2AMAPT | |
| SCHEMBL15904399 | 0.83 | GAA (0.68) | GAAGFERMEN1KMT2AMAPT | |
| SCHEMBL18723653 | 0.83 | GAA (0.68) | GAAGFERMEN1KMT2AMAPT | |
| SCHEMBL2086550 | 0.82 | GAA (0.70) | GAAGFERMEN1KMT2AMAPT | |
| SCHEMBL12845739 | 0.81 | GAA (0.70) | GAAGFERMEN1KMT2AMAPT | |
| SCHEMBL31272020 | 0.81 | GAA (1.00) | GAAGFERMEN1KMT2AMAPT | |
| SCHEMBL16014459 | 0.81 | GAA (0.70) | GAAGFERMEN1KMT2AMAPT | |
| SCHEMBL31271749 | 0.81 | GAA (0.70) | GAAGFERMEN1KMT2AMAPT | |
| SCHEMBL18856549 | 0.81 | GAA (0.70) | GAAGFERMEN1KMT2AMAPT | |
| SCHEMBL15606396 | 0.81 | GAA (0.68) | GAAGFERMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698519-A1 | 3,5-DIAMINOTRIAZOLE DERIVATIVES AND USES THEREOF FOR TREATING OCULAR DISEASES | Centre National de la Recherche Scientifique (FR) | 2026-02-25 | — | — | EP | disclosed |
| WO-2024218236-A1 | 3,5-DIAMINOTRIAZOLE DERIVATIVES AND USES THEREOF FOR TREATING OCULAR DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-10-24 | — | — | WO | disclosed |
| US-20220112166-A1 | Selective JAK2 Pseudokinase Ligands and Methods of Use | YALE UNIVERSITY | 2022-04-14 | — | — | US | disclosed |
| US-9896433-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896433-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9693997-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9693997-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2017-03-23 | — | — | US | disclosed |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2017-03-23 | — | — | US | disclosed |
| US-9540345-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2014-01-09 | — | — | US | disclosed |
| US-8389557-B2 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110082131-A1 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7884119-B2 | protein tyrosine kinase receptor inhibitors such as 3-amino -1-(1H-indol-5-yl)carbonyl-5-[4-2-(pyrrolidin-1-yl)ethoxy]phenylamino]-1H-1,2,4-triazole, used for treating diseases and conditions associated with neovascularization and/or cell proliferation | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7317031-B2 | Substituted triazole diamine derivatives as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317031-B2 | Substituted triazole diamine derivatives as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| CN-100357278-C | Substituted triazole diamine derivatives as kinase inhibitors | ORTHO MCNEIL PHARM INC (US) | 2007-12-26 | — | — | CN | disclosed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| CN-1575284-A | Substituted triazole diamine derivatives as kinase inhibitors | ORTHO MCNEIL PHARM INC (US) | 2005-02-02 | — | — | CN | disclosed |
| US-20040077699-A1 | Substituted triazole diamine derivatives as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | GAA 54/4885GFER 3655/4885MEN1 4566/4885 |
| US-20110082131-A1 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | AXL, TYRO3, FLT3 | GAA 92/4885GFER 3828/4885MEN1 2103/4885 |
| US-20220112166-A1 | Selective JAK2 Pseudokinase Ligands and Methods of Use | JAK2, JAK1, MCL1 | GAA 4046/4885GFER 3753/4885MEN1 3323/4885 |
| US-20040077699-A1 | Substituted triazole diamine derivatives as kinase inhibitors | MAP2K2, PRKDC, MAP2K3 | GAA 2029/4885GFER 4650/4885MEN1 2738/4885 |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | AXL, TYRO3, FLT3 | GAA 427/4885GFER 3513/4885MEN1 3600/4885 |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | GAA 88/4885GFER 3631/4885MEN1 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.